‫ایور کیئر گروپ نے صحت کی دیکھ بھال میں عدم مساوات کے فرق کو ختم کرنے میں مدد کے لیے ایور کیئر فاؤنڈیشن کا آغاز کردیا

– فاؤنڈیشن 2030 کے پائیدار ترقیاتی اہداف میں حصہ لیتے ہوئے افریقہ اور جنوبی ایشیا میں صحت کی دیکھ بھال تک رسائی کو بہتر بنانے کے لیے طویل مدتی حل فراہم کرے گی۔

اسلام آباد، پاکستان، 15 مارچ، 2022/پی آرنیوزوائر/ —  ایور کیئر گروپ نے آج ایور کیئر فاؤنڈیشن کے آغاز کا اعلان کیا، ایک غیر منافع بخش تنظیم جو افریقہ اور جنوبی افریقہ کے کم اور درمیانی آمدنی والے تمام ممالک میں سب کے لیے مساوی صحت اور میں صحت کے مزید لچکدار نظام کی ترقی کے لیے کام کر رہی ہے۔

یہ فاؤنڈیشن ایور کیئر گروپ کے فلاحی ادارے کے طور پر کام کرے گی اور ایور کیئر گروپ کے نقش قدم پر 29 ہسپتالوں، 13 کلینکوں، 88 تشخیصی مراکز کی تعمیر کرے گی اور جو بنگلہ دیش، ہندوستان، پاکستان، نائجیریا، اور کینیا میں 3.3 ملین سے زیادہ لوگوں کی خدمت کرتے ہوئے 11,400 دیکھ بھال کرنے والوں تک رسائی حاصل کرے گی۔

18 ویں دبئی انٹرنیشنل ہیومینٹیرین ایڈ اینڈ ڈیولپمنٹ کانفرنس اور نمائش (DIHAD) سے خطاب کرتے ہوئے، ایور کیئر کے سی ای او میسیمیلیانو کولیلا نے کہا: “فاؤنڈیشن ایک اور اہم شاہراہ  پیش کرتی ہے جس کے ذریعے ہم روایتی طور پر محروم کمیونٹیز کو بامعنی تبدیلی اور مثبت اثرات فراہم کرنا جاری رکھ سکتے ہیں۔ شراکت داری پر مرتکز اور مشاوراتی  سرمایہ کاری کے ذریعے، ایور کیئر فاؤنڈیشن ہمارے تمام شعبوں میں پائیدار ترقی کی تعمیر جاری رکھے گی۔”

کم اور متوسط آمدنی والے ممالک صحت کی دیکھ بھال میں ناکافی سرمایہ کاری کا شکار رہتے ہیں، جس کی وجہ اکثر انتہائی تناؤ اور بوجھ والے نظام ہوتے ہیں جو، خاص طور پر وبائی امراض کے اس دور میں مریضوں کی ضروریات کو پورا کرنے سے قاصر رہتے ہیں ۔ ورلڈ بینک کے مطابق، اگر موجودہ رجحانات جاری رہے تو 2030 تک 5 بلین تک لوگ صحت کی دیکھ بھال تک رسائی حاصل کرنے سے قاصر ہوں گے جب کہ 56 فیصد آبادی عالمی سطح پر دیہی علاقوں میں صحت کی دیکھ بھال کی خاطر خواہ کوریج سے محروم رہے گی۔

ایور کیئر فاؤنڈیشن کی ڈائریکٹر جمُانہ اتوانی نے کہا: “فاؤنڈیشن کمزور کمیونٹیز،  جنہیں اچھی صحت اور تندرستی کا بنیادی حق ہے، کے لیے طویل مدتی مثبت سماجی تبدیلی پیدا کرنے کے عزائم کے تحت چل رہی ہے۔ ایور کیئر فاؤنڈیشن کے ذریعے، ہمارا مقصد ان کمیونٹیز پر توجہ مرکوز کرنا ہے جن کی معیاری صحت کی دیکھ بھال تک رسائی محدود یا بالکل نہیں ہے۔”

‘سب کے لیے مساوی صحت والی دنیا’ کے ہمارے وژن کو عملی جامہ پہنانے کے لیے، فاؤنڈیشن بنیادی طور پر خواتین اور بچوں پر اپنی توجہ مرکوز کرے گی – ترجیحاً خواتین اور لڑکیوں کی نوعمری کی صحت اور بہبود، بشمول قبل از پیدائش اور بعد از پیدائش دیکھ بھال، چھاتی اور سروائیکل کینسر جیسی متعدی بیماریوں کے لئے اسکریننگ  ۔  بچوں کی صحت کے معاملے میں، فاؤنڈیشن پیدائشی پیدائشی نقائص اور ٹراما سے متعلق کیفیات اور بچوں سے متعلق بیماریوں سے بچاؤ اور حفاظتی ٹیکوں کے علاج اور بحالی پر توجہ دے گی۔

بچوں کی مدد پر فاؤنڈیشن کی توجہ کی ایک مثال کینیا سے تعلق رکھنے والی  10 ماہ کی بچی ایلون کی کہانی ہے جو ڈاؤن سنڈروم کا شکار ہے اور اسے سینے میں شدید انفیکشن کے باعث ایور کیئر کے نیروبی خواتین کے ہسپتال میں داخل کیا گیا تھا۔ فاؤنڈیشن نے گروپ کے مربوط میڈیکل کوریڈور کا فائدہ اٹھایا اور اسے زندگی بچانے والی اوپن ہارٹ سرجری کے لیے بھارت میں کیئر ہسپتال منتقل کر دیا گیا، بالکل مفت۔ ہمیں یہ بتاتے ہوئے خوشی ہو رہی ہے کہ بچی ایلون کا آپریشن مکمل طور پر کامیاب رہا، اور وہ ٹھیک ہورہی ہے۔

ایک اور مثال پاکستان سے تعلق رکھنے والے 5 سالہ عبدالرحمان کی ہے، جو پیدائشی طور پر بہرے پن کے ساتھ پیدا ہوا تھا اور جس کا خاندان علاج کا خرچ برداشت نہیں کر سکتا تھا۔ ایور کیئر ہسپتال لاہور کے سرجنوں نے کامیابی کے ساتھ بلا قیمت کوکلیئر امپلانٹ لگایا اور اب عبدل وقتی طور پر سن سکتا ہے اور اسکول جانے کے قابل ہے۔

فاؤنڈیشن صحت کے معاملے میں انسانی وسائل سے متعلق منصوبوں میں یکساں طور پر سرمایہ کاری کرے گی اور ایور کیئر گروپ کے مربوط ہیلتھ کیئر کوریڈور کا فائدہ اٹھا کر صحت کے نظام کو مضبوط بنانے کے لیے کلینکل ٹرائلز اور سرحدوں کے آر پار پیچیدہ صحت کی دیکھ بھال کے معاملات میں مدد کرے گی۔

ایور کیئر فاؤنڈیشن کے بارے میں

ایور کیئر فاؤنڈیشن ایک آزاد انسان دوست تنظیم ہے جو ایور کیئر گروپ کے اثرات کے حامل منصوبوں کی معاونت کے لیے قائم کی گئی ہے۔ فاؤنڈیشن کمزور کمیونٹیز کو معیاری صحت کی دیکھ بھال تک مساوی رسائی فراہم کرتی ہے اور طویل مدتی مثبت سماجی تبدیلی پیدا کرتی ہے۔

فاؤنڈیشن کے ترجیحی شعبے کم اور درمیانی آمدنی والے ممالک میں کمزور کمیونٹیز ہیں، جن کی بنیادی توجہ خواتین اور بچوں پر ہے جو صحت اور سماجی و اقتصادی عدم مساوات کی وجہ سے پسماندہ ہیں۔

ایور کیئر گروپ کے بارے میں

ایور کیئر گروپ صحت کی دیکھ بھال تک رسائی کے ایک بنیادی حق ہونے پر یقین رکھتاہے اور مقامی لوگوں کی ضروریات کو پورا کرنے کے لیے نجی، معیاری صحت کی دیکھ بھال لانے کے لیے ابھرتی ہوئی مارکیٹوں میں سرمایہ کاری کرتا ہے۔

ایور کیئر نے ایک عالمی چیلنج کا جواب دیا ہے اس بات کو یقینی بنایا جائے کہ ابھرتی ہوئی مارکیٹوں  میں رہنے والوں کو ہر عمر میں  پائیدار اقتصادی ترقی کی معاونت کے لیے ایک ستون کے طور پر خوشحالی حاصل ہے۔ اس کے ساتھ، گروپ اپنے مربوط بین البراعظم پلیٹ فارم، اس کے اثرات کے حامل ماڈل، اور معیار کے حامل ہسپتالوں کے ذریعے صحت کی دیکھ بھال کے روایتی ماڈل کو تبدیل کرنے کی راہ پر گامزن ہے۔

ایور کیئر گروپ سارے افریقہ اور جنوبی ایشیا کی ابھرتی ہوئی مارکیٹوں بشمول ہندوستان، پاکستان، بنگلہ دیش، کینیا اور نائیجیریا میں صحت کی دیکھ بھال کے ایک مربوط پلیٹ فارم کے طور پر کام کرتا ہے۔

ایور کیئر مکمل طور پر ایور کیئر ہیلتھ فنڈ کی ملکیت ہے، جو کہ TPG کے زیر انتظام ایک بلین یو ایس ڈالر  (US$1bn) کا ابھرتی ہوئی مارکیٹوں کا ہیلتھ کیئر فنڈ ہے اور اسے عالمی اثرات کی سرمایہ کاری کرنے والے پلیٹ فارم TPG Rise  کا تعاون حاصل ہے۔ ایور کیئر ہیلتھ فنڈ دنیا کے معروف پراثر سرمایہ کاروں اور عالمی ترقیاتی مالیاتی اداروں پر مشتمل ہے۔

Evercare Group launches Evercare Foundation to help bridge the gap in inequality in healthcare

– The Foundation will provide long-term solutions to improve healthcare access in Africa and South Asia, while contributing to the 2030 Sustainable Development Goals.

ISLAMABAD, Pakistan, March 15, 2022 /PRNewswire/ — The Evercare Group today announced the launch of the Evercare Foundation, a non-profit organization working towards equitable health for all and the development of more resilient health systems across the low- and middle-income countries in Africa and South Africa.

The Foundation will serve as the philanthropic arm of the Evercare Group and will build on the footprint of Evercare Group of 29 hospitals, 13 clinics, 88 diagnostic centres and have access to 11,400 caregivers, serving over 3.3 million people in Bangladesh, India, Pakistan, Nigeria, and Kenya.

Speaking at the 18th Dubai International Humanitarian Aid & Development Conference & Exhibition (DIHAD), Massimiliano Colella, CEO of Evercare said: “The Foundation presents another key avenue through which we can continue to deliver meaningful change and positive impact to traditionally underserved communities. Through focused partnerships and deliberate investments, the Evercare Foundation will continue to build sustainable development across our areas of operation.”

Low- and middle-income countries continue to suffer from insufficient investment in healthcare, leading to often highly strained and burdened systems that are unable to keep up with demands of patients, especially in these times of the pandemic. According to the World Bank, if current trends continue, up to 5 billion people will be unable to access health care by 2030 with 56% of the population lacking sufficient health-care coverage in rural areas globally.

Joumana Atwani, Director of Evercare Foundation said: “The Foundation is driven by an ambition to create long-term positive social change for vulnerable communities who have a fundamental right to good health and wellbeing. Through the Evercare Foundation, we aim to focus on communities who have limited or no access to quality healthcare.

To realize our vision of ‘a world with equitable health for all’, the Foundation will primarily focus on women and children – with priority being on women and girls’ adolescent health and wellbeing, including ante and post-natal care, screening for non-communicable diseases such as breast and cervical cancer.  In children’s health, the Foundation will focus on treatment and rehabilitation for congenital birth defects and trauma related conditions and children related disease prevention and immunization.

One example of the Foundation’s focus on supporting children is the story of baby Alvin, a 10-month-old baby from Kenya who suffers from down syndrome and was admitted to Evercare’s Nairobi Women’s Hospital with a severe chest infection. The Foundation leveraged the Group’s integrated medical corridor and was transferred to Care Hospital in India for life saving open-heart surgery, free of charge. We are pleased to report that baby Alvin’s operation was a complete success, and he is doing well.

Another example is of 5-year-old Abdul Rehman from Pakistan, who was born with congenital deafness and whose family could not afford the treatment. Surgeons at Evercare Hospital Lahore successfully inserted a cochlear implant free of cost and now Abdul can hear for the time and able to attend school.

The Foundation will equally invest in initiatives related to human resources in health and leveraging the Evercare Group’s integrated healthcare corridor to strengthen health systems by supporting clinical trials and complex healthcare cases across borders.

About the Evercare Foundation

The Evercare Foundation is an independent philanthropic organization established to support the impact driven initiatives of the Evercare Group.  The Foundation provides vulnerable communities with equitable access to quality healthcare and create long term positive social change.

The priority areas of the Foundation are vulnerable communities in low and middle-income countries, with a primary focus on women and children who are marginalized by health and socio-economic inequities.

About the Evercare Group

The Evercare Group believes access to healthcare is a fundamental right and invests in emerging markets to bring private, quality-driven healthcare to meet the needs of local people.

Evercare has responded to a global challenge to ensure well-being at all ages is provided to those living in emerging markets as a pillar to support sustainable economic development. With this, the Group is leading the way in transforming the traditional healthcare model through its integrated cross-continents platform, its impact-driven model, and quality-driven hospitals.

The Evercare Group operates as an integrated healthcare delivery platform in emerging markets across Africa and South Asia, including India, Pakistan, Bangladesh, Kenya, and Nigeria.

Evercare is wholly owned by the Evercare Health Fund, a US $1bn emerging markets healthcare fund managed by TPG and backed by its global impact investing platform TPG Rise. The Evercare Health Fund is comprised of the world’s leading impact investors and global development finance institutions.

Sweegen Expands Signature Stevia Footprint in Mexico

Mexico has adopted the Codex international food safety authority’s specification for steviol glycosides

Rancho Santa Margarita, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Sweegen’s entire Signature Bestevia® portfolio of nature-based sweeteners and sweetener systems is now accessible to brands in Mexico after the country’s food safety authority adopted the Codex Alimentarius (Codex) specifications for steviol glycosides produced by different technologies. This includes Sweegen’s bioconversion method for producing clean and non-GMO stevia sweeteners, such as Rebaudiosides B, D, E, I, M, and N. Codex is the international food safety organization under the auspices of the World Health Organization (WHO).

“Mexico’s Codex adoption is a step in the right direction for tackling obesity and diabetes in adults and children stemming from high sugar in products,” said Luca Giannone, senior vice president of global sales. “Streamlining the regulatory process for introducing new generation zero-calorie stevia sweeteners contributes to the improvement of overall health and wellness for consumers.”

Giannone further said, “We are eager to share with brands in Mexico our expertise and high-quality ingredients for creating great-tasting, better-for-you product innovations.” He said, “Our robust portfolio of Signature sweeteners and sweetener systems featuring our proprietary Bestevia products is unparalleled; it demonstrates our commitment to investing in new technologies for offering the very best natural sweeteners to brands for tackling the challenges of sugar reduction and replacement in the formulation of food and beverages.”

Adopting the rigorous Codex framework for stevia technologies provided a streamlined approach for reviewing and approving Sweegen’s clean and sustainable bioconversion process. This approval by Mexico will provide greater access to less common and better-tasting steviol glycosides at scale and a more sustainable supply of zero-calorie ingredients with a taste closest to sugar.

Before the adoption, Sweegen’s Rebaudiosides M and D were approved in Mexico through the standard regulatory process. The new regulatory development opens doors for Sweegen to introduce unique Signature sweetener systems to brands, in addition to its Rebs D and M, further expanding product developers’ sugar reduction toolkits.

“With more sugar reduction tools for brands to explore, they can rapidly develop great-tasting and healthy food and beverages, sparking and inspiring new innovations and product launches,” said Giannone.

Sweegen’s LATAM Innovation Studio is located in Mexico City and serves the entire region. It is one of many global creative centers home to product developers exploring sweet taste solutions, local consumer insights, and collaborating on new or reformulated products with Sweegen’s expert food and applications team.

“The Codex framework sets a good regulatory example on welcoming better ingredients for supporting health and wellness,” said Hadi Omrani, senior director of technical and regulatory affairs. “As more countries follow suit, Sweegen’s global stevia footprint will rapidly expand into more countries, providing brands better options in sugar reduction solutions where they are under government pressure, like Mexico, to produce healthy food and beverages.”

Obesity, diabetes, and associated diseases are prevalent in Mexico and are leading public health concerns. Adult obesity increased by 42.2% from 2000 to 2018. Childhood obesity is linked to high sugar consumption and saturated fats. In 2016, Mexico declared an epidemiological alert as a result of high rates of diabetes and obesity after a WHO report published in 2015 raised awareness on serious health issues and supported Mexico’s sugar tax on all nonalcoholic beverages with added sugar in 2014. UNICEF reports that Mexico is the largest consumer of ultra-processed products, including sugary drinks, in Latin American countries.

Mexico’s beverage sugar tax resulted in fewer people buying sodas, with an overall decline of just 7.6%. “Behavioral conditioning through a beverage tax only goes so far,” said Giannone. “Introducing better ingredients into the food and beverage space can breathe new life into product offerings and stimulate new trends, such as plant-based products or functional beverages.”

In 2020, food and beverage producers in Mexico felt more pressure by a government mandate to present new front-of-package labels warning consumers of excess calories, sugar, sodium, saturated fats, and trans-fats, as well as caffeine and artificial sweeteners.

With the Codex adoption, brands have new opportunities to connect with consumers by delivering a full sugar-like taste in food and beverages without the calories. This would be a significant advancement from several years ago when the first generation of stevia was introduced.

Unlike first-generation stevia sweeteners like Rebaudioside A, new generation rebaudiosides made by bioconversion produce clean new generation sweetener molecules like Rebaudiosides B, D, E, I, M, and N, which are originally found in small quantities in the stevia leaf. They impart a clean sugar-like taste with a better sensory profile and are highly sought-after by food and beverage manufacturers in countries with regulatory approvals.

“Brands in Mexico can look to Sweegen as a resource of expertise and as a committed partner for creating zero to low-calorie new product innovations that will delight consumers while supporting the country’s journey on health and wellness goals,” said Steven Chen, Sweegen’s chief executive officer. “We commend the food and safety authorities in Mexico for demonstrating leadership by taking action on adopting the Codex specification.”

About Sweegen

Sweegen provides sweet taste solutions for food and beverage manufacturers around the world.

We are on a mission to reduce the sugar and artificial sweeteners in our global diet.  Partnering with customers, we create delicious zero-sugar products that consumers love.  With the best next-generation stevia sweeteners in our portfolio, such as Bestevia® Rebs B, D, E, I, M, and N, along with our deep knowledge of flavor modulators and texturants, Sweegen delivers market-leading solutions that customers want and consumers prefer. Be well. Choose well.

For more information, please contact info@sweegen.com and visit Sweegen’s website, www.sweegen.com.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Reb M stevia leaf sweetener. These statements are based on current expectations but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of Sweegen, Inc.

Relevant risks and uncertainties include those referenced in the historic filings of Sweegen, Inc. with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and, therefore, should be carefully considered. Sweegen, Inc. assumes no obligation to update any forward-looking statements due to new information or future events or developments.

Attachments

Ana Arakelian
Sweegen
949.709.0583
ana.arakelian@sweegen.com

Conagen Develops Novel High-Performing Debondable Adhesives From Natural Ingredients

Sustainable hot melt adhesives resolve manufacturers from traditional hurdles in bonding

Bedford, Mass., March 15, 2022 (GLOBE NEWSWIRE) — A new era for adhesives has arrived for manufacturers seeking debondable structural adhesive solutions to avoid waste and save costs in manufacturing. Today, Conagen, the biotechnology innovator, announced the development of highly sought-after debondable hot melt adhesives made by high-performance materials from sustainable and natural bio-molecules.

“Conagen has solved the challenges manufacturers face in seeking strong structural adhesives that are long-lasting, perform strongly, and have the valuable option for breaking the adhesion before final finishing operations to deliver perfect products,” said J. McNamara, vice-president of chemical applications.

The advantages of high-strength debondable adhesives benefit multiple industries. For example, smartphones and electronics can be repaired effortlessly, and deconstructed at the end of their life without damaging components for recovery and recycling of valuable parts currently in land refills.

“Conagen’s patented debondable hot melt adhesive are incredibly stronger than what is used in the market now and can outperform petroleum-based products with a sustainable advantage that saves time, cost and reduces waste,” said McNamara.

McNamara further states, “The unexpected boost in performance comes from Conagen’s fermented ingredients already at full industrial scale.” And, “Conagen is open to discussing commercialization opportunities with manufacturers who are interested in a new era of performance materials.”

Adhesives offer many advantages in joining materials, including the ease of use compared to welding, sealing, distributing stress, and environmental resistance. Currently, manufacturers glue two pieces together and wait for a day to cure the bond. If there are imperfections in the bond, the glued products are thrown away because they cannot be unglued, resulting in time and material waste.

Today, most reactive hot melt adhesives rely on post-curing chemistry to develop adhesive strength. A downside to this approach is the curing process is irreversible and, as such, hinders or prevents de-bonding almost entirely.

While the ingredients of Conagen’s hot melt adhesives are commonly found in nature, to develop sustainable debondable adhesives, Conagen leverages its precision fermentation technology to engineer a synthetic pathway independent of plant source materials, creating more efficient and sustainable bio-based ingredients than what can be achieved with chemically-synthesized versions.

Conagen’s inspiration is self-healing materials, using sustainable and natural ingredients, turning them into high-strength debondable hot melt adhesives. “The process is as simple as cutting the plastic that reheals itself in less time than the conventional way,” said McNamara.

The Conagen adhesive is unique as it is a cross-linked material designed with reversibility in mind that exhibits the strength of traditionally cured adhesives with the added benefit of transitioning to a flowable material after heating.

Conagen’s debondable adhesive formulation is ideal for cars, boats, planes, transportation, consumer electronics and appliances, and military and industrial applications. And Adhesives in electric vehicles (EVs) are more widespread than conventional automobiles.

The adhesives market stood at $729.11 billion in 2019 and is projected to exhibit a CAGR of 5.3% between 2020 and 2027, making Conagen’s adhesive formulation lucrative in the original equipment manufacturers (OEM) market.

Conagen’s hallmark in the specialty and industrial space is discovering applications from the platform of natural bio-compounds and bio-materials for a new era of materials that are both high-performing and sustainable.

“Our adhesive formulation continues to show promise for bonding a wide array of materials, such as metal, plastic, and glass,” said McNamara. “We’re making it easier for companies to adopt a more natural position in manufacturing while staying true to the performance of their products.”

About Conagen

Conagen is a product-focused, synthetic biology R&D company with large-scale manufacturing service capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachments

Ana Arakelian
Conagen
+1.781.271.1588
ana.arakelian@conagen.com

Hitachi Energy to accelerate sustainable mobility in Germany’s biggest city

Grid-eMotion™ Fleet smart charging solution to help the City of Berlin reach its goal of a zero-emission bus fleet by 2030

Zurich, Switzerland, March 15, 2022 (GLOBE NEWSWIRE) — Hitachi Energy has won an order from Berliner Verkehrsbe-triebe (BVG), Germany’s biggest municipal public transportation company, to supply its Grid-eMotion™ Fleet smart charging infrastructure to help BVG transition to sustainable mobility in Berlin, the country’s capital.

Hitachi Energy will provide a complete Grid-eMotion Fleet grid-to-plug charging infrastructure solution for the next two bus depots to be converted in the bus electrification program. Hitachi Energy’s solution offers the smallest footprint for both the connection, as well as low noise emissions and high reliability – three key requirements for bus depots in a densely populated urban environment, where space is limited and flawless charging is vital to ensure buses run on time.

The solution comprises a connection to the distribution grid, power distribution and DC charging infrastructure with charging points and smart charging systems. Hitachi Energy will perform the engineering and integrate, install and service the entire solution. The solution has a compact and robust design that requires less equipment than competing infrastructure, which results in a small footprint, lower operating and maintenance costs, and higher reliability. Typically, Grid-eMotion Fleet requires 60 percent less space and 40 percent less cabling than alternative charging systems; it also provides superior overall system reliability.

“We are delighted to help the City of Berlin in its transition to quiet and emission-free transportation and a sustainable energy future for the people of this iconic capital,” said Niklas Persson, Managing Director of Hitachi Energy’s Grid Integration business. “We feel the urgency and have the pioneering technology and commitment to advance sustainable mobility, thus improving the quality of life of millions of people.”

BVG operates Germany’s biggest city bus fleet of around 1,500 vehicles, which it aims to make completely electric and emission-free by 2030. This requires the installation of charging infra-structure in its large network of bus depots.

About Grid-eMotion

Grid-eMotion comprises two unique, innovative solutions – Fleet and Flash. Grid-eMotion Fleet is a grid-code compliant and space-saving grid-to-plug charging solution that can be in-stalled in new and existing bus depots. The charging solution can be scaled flexibly as the fleet gets bigger and greener. It includes a robust and compact grid connection and charging points, and is also available for commercial vehicle fleets, including last-mile delivery and heavy-duty trucks that require high power charging of several megawatts. Grid-eMotion Flash™ enables operators to flash-charge buses within seconds at passenger stops and fully recharge within minutes at the route terminus, without interrupting the bus schedule.

Both solutions are equipped with configurable smart charging digital platforms that can be em-bedded with larger fleet and energy management systems. Additional offerings from Hitachi Energy for EV charging systems consist of e-mesh™ energy management and optimization solutions and Lumada APM, EAM and FSM solutions, to help transportation operators make informed decisions that maximize their uptime and improve efficiency.

In the past few months alone, Hitachi Energy has won orders from customers and partners all over the world for its smart charging portfolio – a sign that Grid-eMotion is changing the e-mobility landscape for electric buses and commercial vehicles. Grid-eMotion solutions are al-ready operating or under development in Australia, Canada, China, India, the Middle East, the United States and several countries in Europe.

About Hitachi Energy Ltd.

Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world’s energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. Headquartered in Switzerland, we employ around 38,000 people in 90 countries and generate business volumes of approximately $10 billion USD.

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company’s consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.

Attachment

Rebecca Bleasdale
Hitachi Energy Ltd.
+41 78643 2613
rebecca.bleasdale@hitachienergy.com

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts

  •  First clinical data demonstrating effectiveness of HGNS to treat CCC patients
  •  As previously disclosed, confirms achievement of primary endpoint of AHI4 reductions for entire population, CCC cohort, and non-CCC cohort at six months, and reports 60%+ responder rates for all three cohorts
  •  Exceeds 70% mean reduction in AHI4 among responders in both CCC and non-CCC cohorts

Mont-Saint-Guibert, Belgium – March 14, 2022, 11:30pm CET / 6:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided additional data from its BETTER SLEEP clinical trial that it showcased in a poster presentation at the 16th World Sleep Congress 2022. World Sleep, a global scientific congress, gathers leaders in sleep medicine and research from around the world for scientific sessions and networking.

Forty-two (42) moderate-to-severe OSA patients in the study received an implant at eight research sites in Australia, 18 of whom presented with Complete Concentric Collapse (CCC) of the soft palate and 24 who were classified as non-CCC. Three patients in each arm did not complete their six-month polysomnography, and as a result, the analysis was calculated based on 36 patients (15 CCC, 21 non-CCC). Of these 36 patients, there were 23 responders (64%), including nine of the 15 CCC patients (60%) and 14 of the 21 non-CCC patients (67%), at six months.

The primary endpoint was achieving at least a 4-point reduction in the apnea-hypopnea index (4% oxygen desaturation, or AHI4) from baseline at six months for the entire 42 patients. The overall reduction was statistically significant with an 11-point reduction (p<0.001), with statistically significant reductions of 10 points (p=0.001) in the CCC cohort and 11 points (p<0.001) in the non-CCC cohort. In addition, mean AHI4 reduction exceeded 70% among responders in both CCC and non-CCC cohorts. These results are subject to final review and validation.

“BETTER SLEEP represents the first clinical study to demonstrate the effectiveness of treating CCC patients with hypoglossal nerve stimulation (HGNS),” said Olivier Taelman, Chief Executive Officer of Nyxoah. “The results give us confidence that we will be able to provide a better treatment option for CCC patients, who comprise approximately 30% of the moderate-to-severe OSA population and are contraindicated for other HGNS options. These data validate our differentiated approach of delivering bilateral stimulation via an implantable device requiring only one incision, and a CCC indication would eliminate the need for patients to undergo an invasive DISE procedure.”

“We are also extremely encouraged to have generated such positive clinical results after just six months following implantation, as the growing body of clinical data and real-world experience suggests that patient responses improve meaningfully between months six and twelve,” continued Mr. Taelman. “The granting of an expanded CE mark indication to treat CCC patients and Breakthrough Device Designation from the U.S. FDA, both based on BETTER SLEEP, along with the high-level interest among the approximately 50 physicians in attendance at Nyxoah’s World Sleep symposium, underscore the strength of the data and excitement for the Genio platform. We continue to work with the FDA on an IDE approval to conduct a clinical trial for CCC patients in the U.S., which we aim to commence later this year.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment